The company has not filed an annual or quarterly report since its Q3 FY2018 10-Q, filed Nov 8, 2018. Its latest SEC filing is a SC 13G/A from Feb 14, 2019.
10-Q for Q3 FY2018, filed Nov 8, 2018
The sections below describe the company as of the FY2017 annual report.
Sells spinal implants, instruments and disposables to hospitals for surgeons treating complex, minimally invasive and degenerative spinal conditions.
10-K for FY2017, filed Mar 1, 2018
Hospitals buy spinal implants, disposables and instruments for surgeries; the sale is counted when a delivered order confirms use in surgery or when advance purchases ship. In distributor markets, distributors buy surgical sets and implant replenishments, typically at shipment.
10-K for FY2017, filed Mar 1, 2018RevenueView ↗
In markets where we have a direct presence, we generally assign our surgical sets to our direct sales employees. A surgical set typically…View ↗
In our international markets where we utilize independent distributors, we generally sell our surgical sets and the related spinal implant…View ↗
$258M
10-K for FY2017, filed Mar 1, 2018
$258M ↗
In the United States and certain international markets, sales are managed directly to hospital customers through direct sales staff and independent sales agencies; in other international markets, distributors buy products and handle hospital billing and surgeon service.
10-K for FY2017, filed Mar 1, 2018The primary market for our products has been the United States, including the territory of Puerto Rico, where we sell our products through…View ↗
We also market and sell our products internationally in 40 countries. We sell our products directly in certain markets such as the United…View ↗
We market and sell spinal implants, disposables and instruments, primarily to hospitals, for use by surgeons to treat patients with spinal…View ↗
In our international markets where we utilize independent distributors, we generally sell our surgical sets and the related spinal implant…View ↗
10-K for FY2017, filed Mar 1, 2018
Financial instruments that potentially subject us to a concentration of credit risk consist principally of cash and cash equivalents and…View ↗
No. It lost $37.1M in .
10-K for FY2017, filed Mar 1, 2018
10-Q for Q3 FY2018, filed Nov 8, 2018
−$15.8MView ↗
8-K, filed Nov 9, 2018
At the Effective Time, each share of common stock, par value $0.001 per share, of the Company (the “Common Stock”) issued and outstanding…View ↗
8-K, filed Aug 30, 2018
On the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the “Effective Time”)…View ↗
Grew. Revenue grew 64% in 4 years, from $157.6M in to $258M in , about 13% a year.
A broader surgical platform
The older report centers on spine technologies and products, while the latest also presents Balance ACS as a platform of products, services and research to help surgeons achieve spinal balance.
10-K for FY2014, filed Mar 18, 2015 10-K for FY2017, filed Mar 1, 2018We are a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine…View ↗
We have also leveraged our core competences into Balance ACS, a comprehensive platform of products, services and research designed to help…View ↗
Loading...
